Inhibikase Therapeutics, Inc.
IKT
$1.94
-$0.15-7.18%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 79.60K | 196.00K | 260.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 79.60K | 196.00K | 260.50K |
| Cost of Revenue | 17.21M | 13.02M | 12.06M | 13.52M | 13.62M |
| Gross Profit | -17.21M | -13.02M | -11.98M | -13.32M | -13.36M |
| SG&A Expenses | 11.38M | 7.04M | 7.03M | 6.84M | 6.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.59M | 20.06M | 19.08M | 20.35M | 20.35M |
| Operating Income | -28.59M | -20.06M | -19.01M | -20.16M | -20.09M |
| Income Before Tax | -27.52M | -19.57M | -18.38M | -19.20M | -19.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.52 | -19.57 | -18.38 | -19.20 | -19.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.52M | -19.57M | -18.38M | -19.20M | -19.03M |
| EBIT | -28.59M | -20.06M | -19.01M | -20.16M | -20.09M |
| EBITDA | -28.56M | -20.04M | -18.98M | -19.98M | -19.91M |
| EPS Basic | -2.21 | -2.72 | -2.81 | -3.09 | -3.34 |
| Normalized Basic EPS | -1.38 | -1.70 | -1.76 | -1.93 | -2.09 |
| EPS Diluted | -2.21 | -2.72 | -2.81 | -3.09 | -3.34 |
| Normalized Diluted EPS | -1.38 | -1.70 | -1.76 | -1.93 | -2.09 |
| Average Basic Shares Outstanding | 94.83M | 28.94M | 26.22M | 24.85M | 23.09M |
| Average Diluted Shares Outstanding | 94.83M | 28.94M | 26.22M | 24.85M | 23.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |